Media Update: EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US
EULAR: rilzabrutinib data in IgG4-related disease show reduction in flares and key disease markers; earns Fast Track designation in the US
- New rilzabrutinib data showed a considerable reduction in disease flares despite glucocorticoid withdrawal, in patients with IgG4-related disease, a rare condition
- Rilzabrutinib recently granted orphan drug designation and fast track designation in the US for IgG4-related disease
Paris, June 12, 2025. New data from a phase 2 study showed that treatment with rilzabrutinib led to a considerable reduction in disease flares and other key disease markers, as well as glucocorticoid (GC) sparing, in patients with active IgG4-related disease (IgG4-RD). The results were presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain, from June 11 to 14, 2025.
John Stone, MD, MPH
Professor of Medicine, Harvard Medical School, the Edward A. Fox Chair in Medicine, Massachusetts General Hospital, and Executive Chairman, The IgG4ward! Foundation
“IgG4-related disease is a progressive immune-mediated rare disease with a significant unmet patient need. While it can inflict irreversible organ damage and can even be fatal in some cases, there are limited approved treatments for this disease. The data presented at EULAR are promising as they support the potential of rilzabrutinib to help manage chronic fibro-inflammatory symptoms, notably by reducing flares and reliance on glucocorticoids in people with IgG4-related disease.”
Key results
The phase 2 study (clinical study identifier: NCT04520451) was an open-label, proof-of-concept, 52-week study in adult patients with a diagnosis of IgG4-RD according to ACR/EULAR 2019 criteria and an IgG4-RD responder index (RI) of ≥2 at screening, with active disease in ≥1 organ system, excluding lymph nodes. Most patients received rilzabrutinib 400mg twice daily plus a GC taper over four weeks, followed by rilzabrutinib alone for the remainder of the 52-week period. The following results were observed:
- 70% of patients treated with rilzabrutinib were flare free at week 52 without additional treatments (GCs or immunosuppressants).
- Clinically meaningful improvements in disease activity were observed at week 52 as assessed by ≥2 point reductions in IgG4-RD RI.
- IgG4-RD RI reductions were evident as early as week 12 which were sustained at week 52.
- Safety profile of rilzabrutinib was consistent with previous studies, with no new safety signals observed. Treatment-emergent adverse events reported by >10% of patients include diarrhea, COVID-19, dizziness, dry mouth and nausea.
Alyssa Johnsen, MD, PhD
Global Therapeutic Area Head, Immunology and Oncology Development
“Sanofi is committed to advancing new medicines in immune-mediated rare diseases, including IgG4-related disease. The promising phase 2 study results presented at EULAR strengthen our confidence in rilzabrutinib and its potential to have a meaningful impact on IgG4-related disease symptoms and disease progression. We look forward to our ongoing development program for rilzabrutinib.”
The US Food and Drug Administration (FDA) granted fast track designation (FTD) in May 2025 and orphan drug designation (ODD) in April 2025 to rilzabrutinib for the treatment of IgG4-RD. FTD is an FDA process designed to facilitate the development, and expedite the review of, medicines to treat serious conditions and fill unmet medical need. The FDA created this process to help deliver important new drugs to patients earlier, and it covers a broad range of serious illnesses. The US FDA grants ODD to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US.
Further development and advancement of rilzabrutinib into a phase 3 program is expected to start later this year. Rilzabrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.
About rilzabrutinib
Rilzabrutinib is a novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK) inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of Sanofi’s TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of off-target side effects.
About IgG4-RD
IgG4-RD is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes-fatal outcome. People with IgG4-RD experience frequent flare-ups of the condition characterized by periods of exacerbated symptoms, which are typically managed with off-label GCs and immunosuppressive drugs, such as rituximab. It affects approximately eight out of 100,000 adult patients in the US each year. Due to its rarity and challenges with diagnosis, the global prevalence of IgG4-RD is unknown.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Investor Relations
Thomas Kudsk Larsen |+44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Felix Lauscher | +1 908 612 7239 | felix.lauscher@sanofi.com
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Tarik Elgoutni | +1 617 710 3587 | tarik.elgoutni@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com
Sanofi forward-looking statements
This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
All trademarks mentioned in this press release are the property of the Sanofi group.
Attachment
